BioSpace News Archive

Silicon Valley-based digital healthcare technology pioneer PROTXX, Inc. today announced a broad collaboration with Alberta-based organizations including Alberta Health Services (AHS), independent clinical healthcare providers, machine learning developers, and three of the province’s universities.

VBI Vaccines Inc. announced that it received notice from the Nasdaq Listing Qualifications Office of The Nasdaq Stock Market LLC on January 9, 2020, indicating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550, and the matter is now closed.

AgeX Therapeutics, Inc. announced that the company will present at the following four conferences this month: Biotech Showcase, January 13-15; Precision Medicine World Conference, January 21-24; World Stem Cell Summit, January 21-24; and Longevity Therapeutics, January 28-30.

Fluidigm Corporation provided preliminary financial highlights for the fourth quarter ended December 31, 2019.

The Medical Affairs Professional Society (MAPS), a global nonprofit, membership-based organization, is pleased to announce Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson, as a keynote speaker at the MAPS 2020 Global Annual Meeting, taking place March 8-11, 2020 at the Miami Beach Convention Center.

Studies to Enroll Approximately 1,200 Patients to Determine Effectiveness of Tavapadon Across the Full Spectrum of Early- and Late-Stage Parkinson’s

XBiotech Inc. announced that it commenced a “modified Dutch auction” tender offer to purchase up to $420,000,000 of its common shares, or such lesser number of common shares as are properly tendered and not properly withdrawn, at a price not less than $30.00 nor greater than $33.00 per common share, to the seller in cash, less any applicable withholding taxes and without interest.

OSE Immunotherapeutics announced that the Japanese Patent Office has issued a new patent family related to Tedopi®, a combination of neoepitopes, protecting the product’s method for inducing early T-lymphocyte memory response for use in the treatment of cancer in HLA-A2 positive patients.

Horizon Discovery Group plc announced that it will provide access to a novel base editing technology licensed from Rutgers, The State University of New Jersey, for exclusive use in therapeutic, diagnostic and services applications.

Athersys, Inc. announced the one-year follow-up summary results from its exploratory clinical study of the intravenous administration of MultiStem® cell therapy to treat patients who are suffering from acute respiratory distress syndrome.